Neuractine 2mg Savi treatment for insomnia (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Eszopiclone

Ingredient

Composition information	Content
Eszopiclone	2mg

Uses

Indications

Neuractine 2 mg is indicated in the following cases:

Eszopiclone is designated to treat insomnia. EszopiClone is unknown, this impact is thought to be the result of interaction with the GABA receptor complex in the cohesion area located near or different from the space to the Benzodiazepine receptors.

Eszopiclone is a Benzodiazepin -free sleeping pills, a pyrrolopyrazin derivative of the cyclopyrolon class.

pharmacokinetic pharmacokinetics

absorption and distribution

Eszopiclone is quickly absorbed after drinking. Plasma peak concentration reaches about 1 hour after drinking. Eszopiclone is weak with plasma proteins (52 - 59%).

Metabolism

After drinking, Eszopiclone is rapidly metabolized by oxidation and demethylation.

Main metabolites in plasma are (S)-Zopiclon-N-OXID and (S) -N-DESMETHYL Zopiclone, N-Desmethyl compound linked to a significant weak GABA receptor compared to Eszopiclone and N-OXIDE compound indicated that there is no important connection to this receptor.

Elimination

After drinking, Eszopiclone is eliminated with an average selling time of about 6 hours. More than 75% of zopiclone racemic dose is excreted into the urine, mainly metabolites. About less than 10% of the oral dose of Eszopiclone is excreted in the urine in the formless form.

Before taking Neuractine 2mg Savi treatment for insomnia (3 blisters x 10 tablets)

How to use

Neuractine 2 mg is taken orally.

Eszopiclone oral with or right after a high -fat meal, the results reduces the absorption and effectiveness of Eszopiclone on sleep latency.

Dosage

Dosage for adults

Eszopiclone dose depends on each individual.

Eszopiclone's initial recommendation for most adults (

The starting dose may be 2 mg or raise to 3 mg if clinically indicated because the 3 mg dose is more effective to maintain sleep.

Dosage for the elderly

Eszopiclone's initial recommendation is 1 mg right before bed for elderly patients who complain mainly about sleep difficulty in these patients. The dose may be increased to 2 mg if clinical indications. For elderly patients who complain that it is difficult to maintain sleep, the recommended dose is 2 mg right before going to bed. The maximum dose is no more than 2 mg/day.

Dosage for people with liver failure

The starting dose of Eszopiclone should only be 1 mg for patients with severe liver failure. EszopiClone should be used cautiously in patients with hepatic failure.

Use with CYP3A4 enzyme inhibitors

The starting dose of Eszopiclone should not exceed 1 mg in patients using Eszopiclone simultaneously with strong CYP3A4 inhibitors. If necessary, the dose can increase 2 mg.

Use with the central nervous system inhibitors

may have to adjust the dose when Eszopiclone is used in combination with central nervous systems due to side effects.

Dosage for children

The safety and effectiveness of Eszopiclone has not been established in children's patients. In clinical studies on insomnia patients associated with attention hyperactivity (ADHD), Eszopiclone failed to prove the effectiveness.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? An intravenous injection may be used when necessary. Flumazenil detoxification is useful.

Similar to all cases of overdose, need to monitor and apply general support for respiration, heart rate, blood pressure and other signs. Hypotension and central nervous system should be monitored and treated with appropriate medical intervention.

The effectiveness of the reference in the treatment of overdose has not been determined.

What to do when forgetting 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Neuractine 2mg, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Systemic effect: chest pain, confusing, staggering, restlessness, changing temperament.

Cardiovascular system: migraine

Systemic effects: allergic reactions, cellular inflammation, face edema, fever, bad breath, body temperature stroke, hernia, discomfort, stiff neck, light sensitivity. Blood, enlarged lymphadenopathy (lymphadenopathy). Remember, neurological disorders, vibration of the eyeball, paresthesia, reduced reflexes, abnormal thoughts, dizziness, abnormal gait. Special senses: conjunctivitis, dry eyes, ear pain, otitis media, tinnitus, vestibular disorders. Dao.

Instructions on how to handle ADR

If you experience serious unwanted effects, stop taking the medication and consult with the treating doctor. To minimize side effects, adhere to the dosage and how to use as instructed by your doctor.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Neuractine medicine 2mg contraindicated in the following cases:

hypersensitively to Eszopiclone. Hypersensitivity reactions include anaphylactic reactions and angiography.

Cases of respiratory failure.

Precautions when using

The central nervous system inhibitors

Eszopiclone may have side effects that inhibit the central nervous system when used with other mental medications, anti -convulsions, antihistamines, ethanols and other drugs that have the effect of inhibiting the central nervous system.

Eszopiclone is not used with alcohol. The dosage may be needed when Eszopiclone is simultaneously used with other central neurological inhibitors, because of the potential side effects.

Time to use drugs

Due to the quick impact after drinking, Eszopiclone is only used just before going to bed or after the patient is about to sleep because of difficulty sleeping. Using sedative/sleeping drugs while having normal activities can lead to short -term memory decline, hallucinations, mobility coordination, dizziness and dizziness.

Used for elderly patients and/or depression.

Improving motor efficiency and/or awareness after exposure many times.

The ability to drive and operate machinery

Patients with ESZOPIClone should be warned about not participating in dangerous jobs that require complete alertness or operating the motor after taking the drug and must be warned about the potential for decline when performing such activities the next day after drinking Eszopiclone.

Pregnancy

There has been no full control well -controlled research conducted in pregnant women. Eszopiclone should only be used during pregnancy if the potential benefits justify the risks of the fetus.

Breastfeeding period

It is not known whether eszopiclone will excrete in breast milk. Eszopiclone should not be used for breastfeeding women.

Drug interaction

The drug impacts on the central nervous system

Ethanol: Has a mental energy effect that is seen when using Eszopiclone with ethanol.

olanzapine: simultaneously use Eszopiclone and olanzapin to reduce the DSST score. This interaction belongs to the pharmaceutical force, there is no change in pharmacokinetics of both drugs.

CYP3A4 inhibitors or touch drugs

CYP3A4 inhibitors: Eszopiclone concentration increases when used with ketoconazole, a powerful CYP3A4 inhibitor.

CYP3A4 induction drugs: The concentration of zopiclon racemic decreases by 80% due to simultaneous use with rifampicin, a strong CYP3A4 induction agent. Used in combination with CYP3A4 stimulants can reduce the concentration and effect of Eszopiclone.

Interaction with drugs with narrow treatment index

Digoxin: A single dose Eszopiclone 3 mg does not affect the pharmacokinetics of digoxin measured in a stable state after the dose of digoxin 0.5 mg twice a day for 1 day and 0.25 mg daily for 6 days.

warfarin: Eszopiclone 3 mg daily orally for 5 days does not affect the pharmacokinetics of (R)- or (S) -Warfarin.

Interaction with drugs with strong protein bonds with plasma

Eszopiclone is weak to plasma proteins, so the distribution of Eszopiclone is not affected by a change in the bond with the protein.

Storage

In the dry place, the temperature does not exceed 30 ° C. Avoid light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.